Pharmaceutical

Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma

Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.

Aug 7, 2024 - 04:00
Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma
Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.
Read the original article

Tags:

Previous Article

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

Next Article

CVC Capital to pay $925 Million to Mallinckrodt for sale of Therakos Business Unit

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Life scientists’ flight to biotech labs stalls important academic research

STAT+: Life scientists’ flight to biotech labs stalls i...

Nov 15, 2023

CDC and social media: The new misinformation war

CDC and social media: The new misinformation war

Feb 7, 2024

Sanofi signs agreement to acquire Inhibrx for $1.7bn

Sanofi signs agreement to acquire Inhibrx for $1.7bn

Jan 23, 2024